Aastrom Biosciences (ASTM) Said FDA Removes Clinical Hold On Phase II IMPACT-DCM Trial
Tweet Send to a Friend
Aastrom Biosciences, Inc. (Nasdaq: ASTM) reported that the FDA has removed the clinical hold from the Company's U.S. Phase II ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
